Medical condition
Colorectal Cancer
Colorectal Cancer is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- capecitabine (CAPECITABINE SANDOZ) Antineoplastic and immunomodulating agents (L01)
- fruquintinib (FRUZAQLA) Antineoplastic and immunomodulating agents (L01)
- human igg1 monoclonal antibody specific for human interleukin-1 alpha (HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH) Antineoplastic and immunomodulating agents (L01)
- pembrolizumab (KEYTRUDA) Antineoplastic and immunomodulating agents (L01)
- nivolumab (OPDIVO) Antineoplastic and immunomodulating agents (L01)
- panitumumab (VECTIBIX) Antineoplastic and immunomodulating agents (L01)
- ramucirumab (CYRAMZA) Antineoplastic and immunomodulating agents (L01)
- regorafenib (STIVARGA) Antineoplastic and immunomodulating agents (L01)
- trifluridine (LONSURF) Antineoplastic and immunomodulating agents (L01)
- ipilimumab (YERVOY) Antineoplastic and immunomodulating agents (L01)
- cetuximab (ERBITUX) Antineoplastic and immunomodulating agents (L01)
- encorafenib (BRAFTOVI) Antineoplastic and immunomodulating agents (L01)
Latest Colorectal Cancer news
Sapience Therapeutics ST316 Shows 47% Response Rate in Phase 2 Colorectal Cancer Trial
ST316, a first-in-class β-catenin antagonist, demonstrated 47% objective response rate and 93% disease control in second-line colorectal cancer patients.
Inhibrx Biosciences to Present Ozekibart (INBRX-109) Clinical Data for Late-Line Colorectal Cancer Treatment
Inhibrx Biosciences will host a webcast on April 21, 2026, to share Phase 1/2 clinical trial results for ozekibart in late-line colorectal cancer patients.
PDS Biotech's PDS01ADC Shows 78% Response Rate in Metastatic Colorectal Cancer Phase 2 Trial
PDS01ADC demonstrates 78% objective response rate vs 35% control in microsatellite stable metastatic colorectal cancer, offering hope for difficult-to-treat patients.
FDA Approves Amgen's Bispecific Antibody for Metastatic Colorectal Cancer
The FDA has approved Amgen's bispecific antibody, providing a new treatment option for patients battling metastatic colorectal cancer.